This week, following up on our recent post about Merck, we had Eyes On their recent bid for Cidara Therapeutics. This time, the acquisition is made to diversify their portfolio further, adding an antiviral asset for Influenza prophylaxis. This asset, CD 388, could provide a new class of prophylaxis, outside of the current vaccines area.

🆕 Introducing AI-Powered Insights in PharmaTell Studio. With the launch of our brand-new “Eyes on Pharma: AI Summary” feature, we’re adding artificial intelligence (AI) to the core of the PharmaTell experience helping our users find relevant insights faster than ever before.

We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.